Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

H-Ras activation and fibroblast-induced TGF-β signaling promote laminin-332 accumulation and invasion in cutaneous squamous cell carcinoma.

Siljamäki E, Rappu P, Riihilä P, Nissinen L, Kähäri VM, Heino J.

Matrix Biol. 2019 Oct 24. pii: S0945-053X(19)30217-3. doi: 10.1016/j.matbio.2019.09.001. [Epub ahead of print]

PMID:
31655292
2.

Complement System in Cutaneous Squamous Cell Carcinoma.

Riihilä P, Nissinen L, Knuutila J, Rahmati Nezhad P, Viiklepp K, Kähäri VM.

Int J Mol Sci. 2019 Jul 19;20(14). pii: E3550. doi: 10.3390/ijms20143550. Review.

3.

Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.

Riihilä P, Viiklepp K, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Peltonen J, Peltonen S, Kähäri VM.

Br J Dermatol. 2019 May 3. doi: 10.1111/bjd.18095. [Epub ahead of print]

PMID:
31049937
4.

Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma.

Lagerstedt M, Huotari-Orava R, Nyberg R, Nissinen L, Farshchian M, Laasanen SL, Snellman E, Mäenpää JU, Kähäri VM.

Arch Gynecol Obstet. 2019 May;299(5):1345-1351. doi: 10.1007/s00404-018-5015-y. Epub 2019 Jan 4.

5.

Long non-coding RNA PICSAR decreases adhesion and promotes migration of squamous carcinoma cells by downregulating α2β1 and α5β1 integrin expression.

Piipponen M, Heino J, Kähäri VM, Nissinen L.

Biol Open. 2018 Nov 14;7(11). pii: bio037044. doi: 10.1242/bio.037044.

6.

European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1401-1424. doi: 10.1111/jdv.14458. Epub 2017 Aug 9.

PMID:
28792092
7.

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1581-1594. doi: 10.1111/jdv.14466. Epub 2017 Aug 8.

PMID:
28786499
8.

Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.

Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Kivisaari A, Kallajoki M, Grénman R, Peltonen J, Peltonen S, Quint KD, Bavinck JNB, Kähäri VM.

Oncotarget. 2017 Jul 11;8(28):45825-45836. doi: 10.18632/oncotarget.17573.

9.

Significant Role of Collagen XVII And Integrin β4 in Migration and Invasion of The Less Aggressive Squamous Cell Carcinoma Cells.

Moilanen JM, Löffek S, Kokkonen N, Salo S, Väyrynen JP, Hurskainen T, Manninen A, Riihilä P, Heljasvaara R, Franzke CW, Kähäri VM, Salo T, Mäkinen MJ, Tasanen K.

Sci Rep. 2017 Mar 22;7:45057. doi: 10.1038/srep45057.

10.

Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma.

Riihilä P, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Grénman R, Peltonen S, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM.

Am J Pathol. 2017 May;187(5):1186-1197. doi: 10.1016/j.ajpath.2017.01.006. Epub 2017 Mar 17.

11.

Expression of claudin-11 by tumor cells in cutaneous squamous cell carcinoma is dependent on the activity of p38δ.

Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Farshchian M, Kivisaari A, Kallajoki M, Raiko L, Peltonen J, Peltonen S, Kähäri VM.

Exp Dermatol. 2017 Sep;26(9):771-777. doi: 10.1111/exd.13278. Epub 2017 Apr 10.

PMID:
27992079
12.

MicroRNA-203 Inversely Correlates with Differentiation Grade, Targets c-MYC, and Functions as a Tumor Suppressor in cSCC.

Lohcharoenkal W, Harada M, Lovén J, Meisgen F, Landén NX, Zhang L, Lapins J, Mahapatra KD, Shi H, Nissinen L, Kähäri VM, Ståhle M, Sonkoly E, Grandér D, Arsenian-Henriksson M, Pivarcsi A.

J Invest Dermatol. 2016 Dec;136(12):2485-2494. doi: 10.1016/j.jid.2016.06.630. Epub 2016 Jul 22.

13.

New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.

Nissinen L, Farshchian M, Riihilä P, Kähäri VM.

Cell Tissue Res. 2016 Sep;365(3):691-702. doi: 10.1007/s00441-016-2457-z. Epub 2016 Jul 14. Review.

PMID:
27411692
14.

Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2.

Farshchian M, Nissinen L, Grénman R, Kähäri VM.

Exp Dermatol. 2017 Jan;26(1):89-92. doi: 10.1111/exd.13109. Epub 2016 Dec 20. No abstract available.

PMID:
27305645
15.

Long Noncoding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity.

Piipponen M, Nissinen L, Farshchian M, Riihilä P, Kivisaari A, Kallajoki M, Peltonen J, Peltonen S, Kähäri VM.

J Invest Dermatol. 2016 Aug;136(8):1701-1710. doi: 10.1016/j.jid.2016.03.028. Epub 2016 Apr 2.

16.

Clinical and Pathological Aspects of Melanoma among Children in Finland.

Rousi E, Koskivuo I, Kaarela O, Kääriäinen M, Kähäri VM.

Acta Derm Venereol. 2016 Jun 15;96(5):718-20. doi: 10.2340/00015555-2346. No abstract available.

17.

Collagens XV and XVIII show different expression and localisation in cutaneous squamous cell carcinoma: type XV appears in tumor stroma, while XVIII becomes upregulated in tumor cells and lost from microvessels.

Karppinen SM, Honkanen HK, Heljasvaara R, Riihilä P, Autio-Harmainen H, Sormunen R, Harjunen V, Väisänen MR, Väisänen T, Hurskainen T, Tasanen K, Kähäri VM, Pihlajaniemi T.

Exp Dermatol. 2016 May;25(5):348-54. doi: 10.1111/exd.12913.

PMID:
26660139
18.

Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC.

Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kähäri VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O'Toole EA.

J Natl Cancer Inst. 2015 Oct 16;108(1). pii: djv293. doi: 10.1093/jnci/djv293. Print 2016 Jan.

PMID:
26476432
19.

Collagen Turnover in Wound Repair--A Macrophage Connection.

Nissinen LM, Kähäri VM.

J Invest Dermatol. 2015 Oct;135(10):2350-2352. doi: 10.1038/jid.2015.246.

20.

EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma.

Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, Ala-Aho R, Kallajoki M, Veräjänkorva E, Honkanen HK, Heljasvaara R, Pihlajaniemi T, Grénman R, Peltonen J, Peltonen S, Kähäri VM.

J Invest Dermatol. 2015 Jul;135(7):1882-1892. doi: 10.1038/jid.2015.104. Epub 2015 Mar 19.

21.

Complement factor I promotes progression of cutaneous squamous cell carcinoma.

Riihilä P, Nissinen L, Farshchian M, Kivisaari A, Ala-Aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM.

J Invest Dermatol. 2015 Feb;135(2):579-588. doi: 10.1038/jid.2014.376. Epub 2014 Sep 3.

22.

Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.

Alpay K, Farshchian M, Tuomela J, Sandholm J, Aittokallio K, Siljamäki E, Kallio M, Kähäri VM, Hietanen S.

PLoS One. 2014 Aug 22;9(8):e105526. doi: 10.1371/journal.pone.0105526. eCollection 2014.

23.

Squamous cell carcinoma of the skin: Emerging need for novel biomarkers.

Kivisaari A, Kähäri VM.

World J Clin Oncol. 2013 Nov 10;4(4):85-90. doi: 10.5306/wjco.v4.i4.85.

24.

Matrix metalloproteinases in inflammation.

Nissinen L, Kähäri VM.

Biochim Biophys Acta. 2014 Aug;1840(8):2571-80. doi: 10.1016/j.bbagen.2014.03.007. Epub 2014 Mar 14. Review.

PMID:
24631662
25.

Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.

Riihilä PM, Nissinen LM, Ala-Aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM.

J Invest Dermatol. 2014 Feb;134(2):498-506. doi: 10.1038/jid.2013.346. Epub 2013 Aug 12.

26.

p38δ mitogen-activated protein kinase regulates the expression of tight junction protein ZO-1 in differentiating human epidermal keratinocytes.

Siljamäki E, Raiko L, Toriseva M, Nissinen L, Näreoja T, Peltonen J, Kähäri VM, Peltonen S.

Arch Dermatol Res. 2014 Mar;306(2):131-41. doi: 10.1007/s00403-013-1391-0. Epub 2013 Jul 16.

PMID:
23856837
27.

TGF-β-elicited induction of tissue inhibitor of metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between Smad3, p38α, and ERK1/2.

Leivonen SK, Lazaridis K, Decock J, Chantry A, Edwards DR, Kähäri VM.

PLoS One. 2013;8(2):e57474. doi: 10.1371/journal.pone.0057474. Epub 2013 Feb 28.

28.

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J.

Cancer Discov. 2013 Feb;3(2):182-97. doi: 10.1158/2159-8290.CD-12-0292. Epub 2013 Jan 10.

29.

MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability.

Toriseva M, Laato M, Carpén O, Ruohonen ST, Savontaus E, Inada M, Krane SM, Kähäri VM.

PLoS One. 2012;7(8):e42596. doi: 10.1371/journal.pone.0042596. Epub 2012 Aug 7.

30.

ADAMTS5: A New Player in the Vascular Field.

Nissinen L, Kähäri VM.

Am J Pathol. 2012 Sep;181(3):743-5. doi: 10.1016/j.ajpath.2012.07.002. Epub 2012 Jul 20.

PMID:
22824241
31.

Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells.

Toriseva M, Ala-aho R, Peltonen S, Peltonen J, Grénman R, Kähäri VM.

PLoS One. 2012;7(3):e33041. doi: 10.1371/journal.pone.0033041. Epub 2012 Mar 12.

32.

Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats.

Endo H, Niioka M, Sugioka Y, Itoh J, Kameyama K, Okazaki I, Ala-Aho R, Kähäri VM, Watanabe T.

Pathobiology. 2011;78(5):239-52. doi: 10.1159/000328841. Epub 2011 Aug 17.

33.

Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM.

Am J Pathol. 2011 Sep;179(3):1110-9. doi: 10.1016/j.ajpath.2011.05.012. Epub 2011 Jul 1.

34.

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Bradshaw AC, Parker AL, Duffy MR, Coughlan L, van Rooijen N, Kähäri VM, Nicklin SA, Baker AH.

PLoS Pathog. 2010 Oct 7;6(10):e1001142. doi: 10.1371/journal.ppat.1001142.

35.

Forty years of the European Society for Dermatological Research as European dermatology goes from strength to strength.

Healy E, Piguet V, Kähäri VM.

J Invest Dermatol. 2010 Aug;130(8):1957-9. doi: 10.1038/jid.2010.160. No abstract available.

36.

Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.

Kivisaari AK, Kallajoki M, Ala-aho R, McGrath JA, Bauer JW, Königová R, Medvecz M, Beckert W, Grénman R, Kähäri VM.

Br J Dermatol. 2010 Oct;163(4):726-35. doi: 10.1111/j.1365-2133.2010.09924.x. Epub 2010 Sep 2.

PMID:
20586780
37.

Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion.

Heikkinen PT, Nummela M, Jokilehto T, Grenman R, Kähäri VM, Jaakkola PM.

Cancer Res. 2010 Jul 15;70(14):5984-93. doi: 10.1158/0008-5472.CAN-09-3777. Epub 2010 Jun 15.

38.

Protodynamic intracellular acidification by cis-urocanic acid promotes apoptosis of melanoma cells in vitro and in vivo.

Laihia JK, Kallio JP, Taimen P, Kujari H, Kähäri VM, Leino L.

J Invest Dermatol. 2010 Oct;130(10):2431-9. doi: 10.1038/jid.2010.151. Epub 2010 Jun 3.

39.

TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway.

Kallio JP, Hopkins-Donaldson S, Baker AH, Kähäri VM.

Int J Cancer. 2011 Feb 15;128(4):991-6. doi: 10.1002/ijc.25404.

40.

Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.

Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grénman R, James HA, Edwards DR, Kähäri VM.

Clin Cancer Res. 2010 Apr 1;16(7):2022-35. doi: 10.1158/1078-0432.CCR-09-2525. Epub 2010 Mar 21.

41.

Hypoxia-activated Smad3-specific dephosphorylation by PP2A.

Heikkinen PT, Nummela M, Leivonen SK, Westermarck J, Hill CS, Kähäri VM, Jaakkola PM.

J Biol Chem. 2010 Feb 5;285(6):3740-9. doi: 10.1074/jbc.M109.042978. Epub 2009 Dec 1.

42.

Matrix metalloproteinase (MMP)-7 in salivary gland cancer.

Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R.

Acta Oncol. 2010;49(1):85-90. doi: 10.3109/02841860903287197.

PMID:
19929564
43.

Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer.

Luukkaa H, Klemi P, Leivo I, Mäkitie AA, Irish J, Gilbert R, Perez-Ordonez B, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R.

Head Neck. 2010 Aug;32(8):1019-27. doi: 10.1002/hed.21277.

PMID:
19902536
44.

Stromal collagenase in melanoma: a vascular connection.

Kähäri VM, Ala-Aho R.

J Invest Dermatol. 2009 Nov;129(11):2545-7. doi: 10.1038/jid.2009.298.

45.

CCHCR1 is up-regulated in skin cancer and associated with EGFR expression.

Suomela S, Elomaa O, Skoog T, Ala-aho R, Jeskanen L, Pärssinen J, Latonen L, Grénman R, Kere J, Kähäri VM, Saarialho-Kere U.

PLoS One. 2009 Jun 24;4(6):e6030. doi: 10.1371/journal.pone.0006030.

46.

Proteinases in cutaneous wound healing.

Toriseva M, Kähäri VM.

Cell Mol Life Sci. 2009 Jan;66(2):203-24. doi: 10.1007/s00018-008-8388-4. Review.

PMID:
18810321
47.

Diagnostic and prognostic role of matrix metalloproteases in cancer.

Vihinen P, Ala-Aho R, Kähäri VM.

Expert Opin Med Diagn. 2008 Sep;2(9):1025-39. doi: 10.1517/17530059.2.9.1025.

PMID:
23495924
48.

Extended release of adenovirus from silica implants in vitro and in vivo.

Kangasniemi L, Koskinen M, Jokinen M, Toriseva M, Ala-Aho R, Kähäri VM, Jalonen H, Ylä-Herttuala S, Moilanen H, Stenman UH, Diaconu I, Kanerva A, Pesonen S, Hakkarainen T, Hemminki A.

Gene Ther. 2009 Jan;16(1):103-10. doi: 10.1038/gt.2008.142. Epub 2008 Aug 28.

PMID:
18754041
49.

Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer.

Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R.

Acta Otolaryngol. 2008 Apr;128(4):482-90. doi: 10.1080/00016480801922895.

PMID:
18368586
50.

Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.

Kivisaari AK, Kallajoki M, Mirtti T, McGrath JA, Bauer JW, Weber F, Königová R, Sawamura D, Sato-Matsumura KC, Shimizu H, Csikós M, Sinemus K, Beckert W, Kähäri VM.

Br J Dermatol. 2008 Apr;158(4):778-85. doi: 10.1111/j.1365-2133.2008.08466.x. Epub 2008 Feb 16.

PMID:
18284387

Supplemental Content

Loading ...
Support Center